FibroBiologics, Inc. Announces Amendment to At-The-Market Offering — Increases Maximum Common Stock Issuance to \$7.5 Million

Houston, TX, May 6, 2026 — FibroBiologics, Inc. (“the Company”, Nasdaq: FBLG), a Houston-based biotechnology firm specializing in pharmaceutical preparations, has announced a significant amendment to its previously disclosed At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, acting as the Sales Agent. This development comes as the Company filed a new prospectus supplement on May 5, 2026, which increases the maximum aggregate offering price of common stock that may be issued and sold through the ATM program to up to \$7,500,000.

Key Details of the ATM Offering Amendment

• ATM Sales Agreement: The Company originally entered into the ATM agreement on May 1, 2026. The agreement allows FibroBiologics to issue and sell shares of its common stock, par value \$0.00001 per share, from time to time through or to H.C. Wainwright as agent or principal.
• Updated Prospectus Supplement: The new supplement, filed May 5, 2026, increases the total value of common stock issuable under the ATM program to \$7.5 million. This is a material increase from the prior arrangement and may allow the Company to raise additional capital more flexibly.
• Sales to Date: As of the filing, the Company has already sold 71,830 shares under the Sales Agreement.
• Shelf Registration: The shares sold under this program are covered by the Company’s shelf registration statement on Form S-3 (Registration No. 333-284663), which was initially filed with the SEC on February 3, 2025, and became effective on February 10, 2025.
• Legal Opinion: In connection with the filing, the Company included the opinion and consent of its counsel, Sichenzia Ross Ference Carmel LLP, regarding the validity of the shares. These documents are filed as Exhibits 5.1 and 23.1, respectively, and are incorporated into the current 8-K report by reference.

Potential Impact for Shareholders

• Dilution Risk: The substantial increase in the maximum amount of common stock that may be issued under the ATM offering means existing shareholders face the risk of dilution if the Company sells a significant volume of new shares at prevailing market prices.
• Capital Flexibility: The expanded ATM program gives FibroBiologics greater flexibility to raise capital as needed, which could be beneficial for funding operations, research and development, or corporate initiatives without the need for a large, single financing event.
• Price Sensitivity: Increases in authorized ATM sales can sometimes exert downward pressure on share prices, especially if the market anticipates future dilution or if large blocks are sold in the open market. Investors should monitor the pace of new share issuance and how proceeds are utilized.
• Emerging Growth Company Status: FibroBiologics remains classified as an emerging growth company under SEC rules, which may afford it certain reduced reporting obligations but also signals its early-stage development profile.

Summary Table

Cautionary Statement

This Form 8-K filing explicitly notes that it does not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock. No such offer or sale will occur in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under applicable securities laws.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information presented is based on filings made by FibroBiologics, Inc. with the U.S. Securities and Exchange Commission as of May 6, 2026, and may not reflect subsequent developments. The Company’s plans, projections, and statements about future events are subject to risks and uncertainties that could cause actual results to differ materially.

View FibroBiologics, Inc. Historical chart here